 |
answer text |
<p>NHS England does not believe that the closure of the Commissioning Support Programme
will leave a gap in the review of treatments.</p><p>The topics that would have been
referred to the Commissioning Support Programme will now be routed to the appropriate
appraisal programme, undertaken by the National Institute for Health and Care Excellence
(NICE), except where there is a clear rationale not to do so. NICE expects to implement
this expansion from April 2020. It will be in a position to start progressing topics
through the NICE topic selection process from the summer of 2019.</p><p>All policy
propositions relating to topics previously being supported in development through
the Commissioning Support Programme have been handed over at the agreed stage as for
all topics, post stakeholder testing. These are now being progressed though the usual
development process. This process is set out in ‘Methods: National Clinical Policies’
at the following link:</p><p><a href="https://www.england.nhs.uk/publication/methods-national-clinical-policies/"
target="_blank">https://www.england.nhs.uk/publication/methods-national-clinical-policies/</a></p><p>The
voluntary scheme agreed between Department and the Association of the British Pharmaceutical
Industry on getting the best value and most effective medicines into use more quickly
for branded medicines pricing and access was published in November 2018. The voluntary
scheme started on 1 January 2019 and will be in place for five years until 2023.</p>
|
|
